Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Use of deep learning-accelerated T2 TSE for prostate MRI: Comparison with and without hyoscine butylbromide admission.

Magnetic resonance imaging·2025
Same author

MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.

European radiology·2024
Same author

MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer.

European journal of radiology·2024
Same author

Benefit of dynamic contrast-enhanced (DCE) imaging for prostate cancer detection depending on readers experience in prostate MRI.

Clinical radiology·2024

Related Experiment Video

Updated: Mar 9, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.3K

Residual tumor resection (RTR).

A Lusch1, P Albers2

  • 1Department of Urology, Heinrich-Heine University Dusseldorf, Moorenstrasse 5, 40225, Düsseldorf, Germany. achim.lusch@med.uni-duesseldorf.de.

World Journal of Urology
|December 23, 2016
PubMed
Summary
This summary is machine-generated.

Surgical resection of residual testicular tumors is crucial for advanced cases, especially non-seminomas post-chemotherapy. This complex surgery, often requiring additional procedures, demands specialized centers due to potential complications.

Keywords:
Additional surgical proceduresResidual tumor resection (RTR)Testicular cancer

More Related Videos

Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection
08:23

Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection

Published on: May 9, 2022

5.1K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K

Related Experiment Videos

Last Updated: Mar 9, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.3K
Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection
08:23

Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection

Published on: May 9, 2022

5.1K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Urology

Background:

  • Residual tumor resection is a key component of multimodal therapy for advanced testicular tumors.
  • Treatment indications have evolved, with surgery being essential for non-seminomas but rare for seminomas post-chemotherapy/radiotherapy.

Purpose of the Study:

  • To outline the indications for residual tumor resection in advanced testicular cancer.
  • To detail surgical techniques, including necessary adjunctive procedures.
  • To describe common peri- and postoperative complications.

Main Methods:

  • Review of treatment indications and surgical approaches for residual testicular tumors.
  • Description of operative techniques, including adjunctive surgeries like nephrectomy, colectomy, and vascular interventions.
  • Analysis of common peri- and postoperative complications.

Main Results:

  • Surgery is mandatory for most non-seminomatous testicular tumors after chemotherapy.
  • Advanced seminomas rarely require surgical intervention post-treatment.
  • Complex adjunctive procedures (nephrectomy, colectomy, vascular resection) may be necessary.
  • Significant peri- and postoperative complications can occur.

Conclusions:

  • Residual tumor resection is vital for advanced non-seminomatous testicular cancer.
  • Surgical management is complex, requiring specialized high-volume centers.
  • Careful patient selection and surgical planning are essential to minimize complications.